Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, has signed an agreement with Syensqo to distribute its Solef® Polyvinylidene Fluoride (PVDF) materials in North America. The agreement expands access to this critical material known for its combination of chemical resistance and flexibility. Solef® PVDF joins a growing list of high-performance materials in Formerra's portfolio designed to advance product development and innovation."With this new agreement, Formerra will be able to support customers across multiple markets with the materials they need to meet demanding application requirements," said Bob Long, Business Development Manager at Formerra. "In addition, this reinforces our commitment to delivering unmatched access, application support, and advanced materials for customers navigating complex performance and regulatory challenges."PVDF is positioned near the top of the performance pyramid for its outstanding chemical and heat resistance. Its inherent flexibility further enhances its suitability for demanding applications in chemical processing, healthcare, and automotive industries. Key properties* include:Heat resistance: Continuous use temperatures up to 150 degrees C (302 degrees F), bursting pressures of up to 139 bar (2,017 psi) at room temperatureChemical purity: Ultra-pure water resistivity, meeting SEMI F-57 specifications for the semiconductor industryBalance of strength and flexibility: Tensile yield strength up to 55 MPa (8,000 psi) with elongation at break up to 100%"We chose Formerra as our distribution partner for Solef® PVDF in North America because of their technical and commercial reach," said Rose Catherin, Sales Director Americas, Channel partners, Distribution and Digital Sales at Syensqo Specialty Polymers. "Their commitment to excellence and long-standing presence in critical markets make them an ideal fit to help expand the availability and use of Solef® PVDF."*As measured by TDSCaption: Formerra Becomes North American Distributor for Syensqo Solef®PVDF.Key Details:Formerra is an authorized distributor of Solef® PVDF from Syensqo in North America.The agreement includes support for high-performance applications across a broad spectrum of industries.PVDF offers excellent chemical resistance, thermal stability, and flexibility.Formerra provides technical guidance and supply chain expertise to support material selection and application development.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

WESTLAKE, OH, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - GEON® Performance Solutions, a global leader in the formulation, development and manufacture of performance polymer solutions, announced today that it received Great Place To Work® (GPTW) certifications for its USA, Canada, Mexico and China locations. Since partnering with GPTW in 2021, GEON's cultural and sustainability vision is to achieve this recognition each year.GPTW Certified GEON is Great Place to Work-Certified in the US, Canada, Mexico and China.GPTW asks employees to quantify and benchmark their experience, workplace culture and leadership behaviors which are proven to deliver market-leading revenue, employee retention and increased innovation."We are thrilled to receive Great Place To Work recognition in all four countries in which we operate for two consecutive years. Great Place To Work companies are evaluated against top employers globally, so this is a testament that our journey to cultural excellence is on the right track," said GEON Chief Executive Officer Tracy Garrison. "We believe leaders in the marketplace must also be leaders in the workplace. To do this, we nurture a positive work culture everywhere we operate while striving to grow in areas that still need improvement."GEON received a 79 percent engagement rating which exceeds the typical company by over 20 percent. GEON's score improved year-over-year in the U.S., Canada and China and held steady in Mexico. The U.S. survey included the full scope of GEON employees, including employees from Foster, LLC which GEON acquired in January of 2025.According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a Certified™ great workplace. Additionally, employees at Certified workplaces are 93 percent more likely to look forward to coming to work and are twice as likely to be paid fairly and have a fair chance at promotion."Like the data show, achieving GPTW certification is not only a reflection of our culture, but it directly impacts our ability to retain good people who are excited to come to work each day," said GEON Chief Human Resources Officer Jerome Beguerie. "This has a direct impact on our customers and their experience with us."About GEON Performance SolutionsGEON® Performance Solutions is a leading innovator in the development of polymer compounding solutions for a broad range of markets including building & infrastructure, consumer, industrial, transportation, and power & communications. With the acquisition of Foster, LLC, GEON has enhanced participation in the high-growth healthcare and medical device industry and builds on a portfolio of highly adaptable vinyl, polyolefin and engineered resin technologies as well as a full-service contract manufacturing business. GEON has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. GEON is a portfolio company of SK Capital Partners.About SK CapitalSK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.Contact InformationRenita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953SOURCE: GEON Performance Solutions Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - China Lilang Limited (“China Lilang” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1234) today announced its interim results for the six months ended 30 June 2025.Mr. Wang Dong Xing, Chairman and Non-Executive Director of China Lilang, said: “In the first half of 2025, international trade environment became increasingly harsh and complex. During the period, consumer spending in the mainland gradually recovered, but consumers remained cautious about spending on non-essential goods. China Lilang prides a well-differentiated brand matrix that has enabled it to penetrate and have a strong foothold in the menswear market. It appealed to its target customer base through precise product positioning and channel strategies, and launched a number of ‘LILANZ’ and ‘LESS IS MORE’ brand products to meet the needs of the consumer market. In addition, the Group actively deployed omni-channel marketing to enhance the popularity of the Lilang brands and improve the efficiency of online and offline sales channels to boost overall sales and operational competence.”For the six months ended 30 June 2025, the Group’s revenue increased by 7.9% to RMB1,727 million. Among this, revenue of the smart causal collection and other collections urged 31.8%, mainly driven by strong performance in in-store sales of the smart casual collection and new retail business. The core collection recorded a slight decrease of 0.2%, primarily due to one-off revenue deduction resulting from the promotion of DTC business model in Shandong Province and Chongqing City.Gross profit margin increased by 0.2 percentage points year-on-year to 50.2%, mainly due to the increase in average unit price as a result of higher proportion of the direct-to-retail operation in sales revenue. Profit attributable to equity shareholders for the period was RMB242.5 million (2024 Interim: RMB280.1 million). Profit margin attributable to equity shareholders was 14.0%. Earnings per share were RMB20.2 cents.During the period, the Group maintained a healthy financial position with sufficient cash flow. The Board of Directors has recommended payment of an interim dividend of HK11 cents (2024 Interim: HK13 cents) per ordinary share and a special interim dividend of HK5 cents (2024 Interim: HK5 cents) per ordinary share, thereby maintaining a stable payout ratio.The Group diligently advanced its strategic transformation during the period, plus continued to implement its “Multi-brands and Internationalization” development strategy to expand business. The core collection “LILANZ” has continued to consolidate its competitive advantage in the traditional menswear market and successfully amplified its brand awareness and market share. The repurchase and transformation of distribution and agency rights in North-Eastern China and Jiangsu Province were completed last year. During the period, the Group has repurchased the operating rights from distributors in the entire Shandong province and Chongqing city and adopted the DTC model. The "LESS IS MORE" smart casual collection that targets younger consumers continued to operate in a fully direct-to-retail mode. The newly opened stores of the smart casual collection were mainly in South-Western China and Central and Southern China. As at 30 June 2025, there were 2,443 stores for the core collection and 331 stores for the smart casual collection.During the period, the Group continued to optimize its sales channels, opening new stores in shopping malls and outlet stores in prime locations as planned. By incorporating tech-savvy visual aesthetics and youthful, fashionable layouts, the Group has brought the brand’s“Simplicity but not Simple” philosophy to life, thereby enhancing its brand image and driving sales. As at June 30, 2025, the number of stores located in shopping malls rose to 957 (31 December 2024: 933), the store count of outlet stores increased to 121 (31 December 2024: 103), with a total of 2,774 retail stores.The Group completed strategic transformation of its new retail business, upgrading it from an inventory clearance channel into a major new product sales platform, which reported a remarkable 24.6% increase in revenue for the period. While continuing to strengthen its presence on established sales platforms like Tmall, JD.com and TikTok, the Group has also expanded into emerging channels such as Pinduoduo, Wechat Channels and Poizon, creating diversified online sales network all together. It has kept enhancing its e-commerce strategy and leveraged social media platforms such as Xiaohongshu and Weibo to keep releasing high-quality content. This approach has deepened its emotional connection with consumers and presented it with new business opportunities.In terms of“Multi-brands and Internationalization” development strategy, the business of “MUNSINGWEAR” was successfully handed over to the Group in the first half of the year. The Group plans to open its first batch of physical stores in the second half of the year. The Group has opened its first store in Malaysia, which started trial operation in May, marking a significant step in overseas expansion.For the research, development and innovation and brand marketing, the Group is committed to achieving breakthroughs in fabrics, craftsmanship and technologies by pursuing proprietary research and development across its industrial chain, with the goal of enhancing the brand's core competitive advantages. During the period, the Group’s original durable white non-iron shirts, “Water Repellent Down 3.0” and the wash-resistant polo shirts have obtained multiple certifications for their anti-wrinkle, quick-drying, and wash-resistant features, successfully driving sales growth. To step up brand transformation aiming at youth consumers, the Group has harnessed celebrity influence, collaborated with cultural IPs, and employed immersive marketing tactics to engage consumers across various age groups and city tiers.Looking ahead to the second half of 2025, the development of domestic consumer market continues to be challenging. As an industry leader, China Lilang will press on with applying its strengths, following shifts in the consumer market and technological advancement, to promote transformation and to enhance brand influence, achieving sustainable sales and profit growth.In the second half year, the Group will continue to push forward with transformation. It will continue to capitalize on the operational advantages of the DTC model in North- Eastern China, Jiangsu Province, Shandong Province and Chongqing City to achieve healthy expansion, tailoring implementation taking into account the specific conditions of each market to further achieve optimal operational performance. For the smart casual collection, which is operated entirely in the direct-to-retail mode, will have its development foundation strengthened to help maintain its strong development momentum. The Group expects the DTC model to unleash its potential further in the second half year and contribute to sales growth.On the other hand, the Group will continue to leverage the advantages of its sales channel reform, focusing on opening stores in prime locations in premium shopping malls in provincial capitals and prefecture-level cities, and closing the underperforming stores to achieve better overall store performance. At the same time, the Group will prudently expand the layout of outlet stores and increase the number of stores to speed up inventory clearance. The Group aims to achieve a net increase of 50-100 stores in 2025.To achieve both the online and offline development, the Group will accelerate its new retails business by leveraging various platforms to engage young customer groups and strengthen brand market penetration. By increasing brand exposure through multi-dimensional initiatives, the Group aims to increase online sales of new products, expecting a rise to 80% of total e-commerce sales. It will work on optimizing the respond time of its supply chain to meet customers’ needs, via including continuously upgrading its the smart logistics center.With a solid domestic foundation, the Group is confident of accelerating implementation of its “Multi-brands and Internationalization” development strategy. As a key project of its multi-brand strategy, "MUNSINGWEAR" will continue to focus on product development in the second half year to meet the needs of the new middle class for personalized, functional and sustainable fashion. For its overseas business, the Group will open more stores in Malaysia in the second half year to better tap the Malaysian market, as well as actively deploy plans to expand business coverage to other Southeast Asian markets. Furthermore, the Group will promote its brand popularity through collaboration with IPs, as well as enhancing interaction with consumers through precise social media marketing and membership programs to foster customer loyalty and capture bigger market share.Mr. Wang Dong Xing, Chairman of China Lilang, concluded: “While China's consumer market remains challenging, the Group maintains cautious optimism toward the retail sector given the government's implementation of multiple consumption-stimulus measures. The ‘LILANZ’ core collection and the ‘LESS IS MORE’ smart casual collection have both undergone innovative transformation, emerging with clearer positioning. This will enable the Group to enhance precision and efficiency in product development, design, marketing promotion and sales, and ultimately drive the long-term growth. On the other hand, as a steadfast practitioner of sustainable development, the Group has deeply embedded ESG principles into its corporate strategy, consistently driving green innovation and social shared value. During the period, we issued our first independently compiled ESG report titled "Creat a Better Life Together" and formally established an ESG Management Committee, integrating ESG governance into strategic planning and core values – demonstrating our commitment to long-term value creation. Notably, the Group achieved an MSCI ESG rating upgrade to BB, ranking among China's top menswear industry peers. Looking ahead, the Group will continue to reinforce its leadership in the domestic menswear sector and strive to achieve sustainable growth through implementing flexible marketing strategy and continuous innovation, to the ultimate end of generating greater value for shareholders, its employees and customers."About China LilangChina Lilang is one of the leading PRC menswear enterprises. As an integrated fashion enterprise, the Group designs, sources and manufactures high-quality business and casual apparel for men and sells under brands of 'LILANZ' and 'LESS IS MORE' across an extensive distribution network, mainly covering 31 provinces, autonomous regions and municipalities in the PRC. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. The Company demonstrated robust growth momentum and significant operational optimization during the reporting period, with key financial metrics delivering exceptional performance. Notably, its respiratory intervention product portfolio fueled a substantial revenue surge, marking accelerated commercialization progress.Respiratory Intervention Products Emerge as Core Growth Engine, Highlighting Global Competitive EdgeThe Company recorded revenue of RMB51.1 million for the first half of 2025, a 162.4% increase from RMB19.5 million in the same period of 2024, setting a new historical high. This growth was primarily attributable to the strategic focus on respiratory intervention products entering a harvest phase: The Malignant Stenosis Cryoablation System, approved by China’s National Medical Products Administration (NMPA) in March 2025, and the previously commercialized Cryoadhesion System, experienced rapid sales expansion, becoming the dominant revenue drivers. Additionally, the distribution partnership with Boston Scientific’s China affiliate, BSC International Medical Trading (Shanghai) Co., Ltd. (“BSC”), contributed significant incremental revenue from other respiratory intervention products in mainland China.Of particular significance, the Company’s Asthma Cryoablation System received "Breakthrough Medical Device" designation from the U.S. Food and Drug Administration (FDA) – the first such international recognition for a Chinese enterprise in the respiratory interventional cryotherapy field – laying a foundation for global market expansion.Cryofocus has established a highly competitive respiratory intervention portfolio addressing critical indications, including malignant stenosis, benign stenosis, asthma, chronic obstructive pulmonary disease (COPD), peri-pulmonary nodules, chronic cough, and airway tuberculosis. Among these: The Malignant Stenosis Cryoablation System has been successfully commercialized in China; systems for asthma and COPD are in confirmatory clinical trials with expected approvals in 2026; products for cough, tuberculosis, and peri-pulmonary nodules are in various R&D stages; and the Cryoadhesion System (including disposable and re-sterilizable cryoprobes) is approved and marketed. These innovations mainly stem from Cryofocus’s two core technology platforms: unique liquid nitrogen-based cryoablation technology (utilizing liquid nitrogen as the cryogenic energy source) and advanced flexible catheter technology. This integrated platform enables deep low-temperature treatment, precise control, and minimally invasive intervention, offering superior therapeutic efficacy and safety while creating significant technological barriers for competitors.Platform Value Multiplies as Multi-Segment Strategy Accelerates CommercializationCryofocus’s core value extends beyond its respiratory pipeline, underpinned by its distinction as an innovative cryotherapy platform enterprise. Leveraging its liquid nitrogen and flexible catheter technologies, the Company has successfully expanded into multiple high-potential therapeutic areas:In the vascular intervention segment: The Atrial Fibrillation (AF) Cryoablation System (for atrial fibrillation treatment) was commercialized in China in September 2024. The Cryofocus Renal Denervation (Cryo-RDN) System (for hypertension treatment), granted FDA Breakthrough Device designation, is in confirmatory clinical trials. The Pulmonary Hypertension Cryoablation System is currently in the stage of pre-clinical study. The market space for all these related cardiovascular indications is very huge.In the Natural Orifice Transluminal Endoscopic Surgery (NOTES) segment: The respiratory intervention portfolio, as detailed, is rich and leading. The cancer intervention portfolio includes the commercialized Bladder Cryoablation System; the Gastric Cryoablation System and Esophageal Cryospray System are in clinical trials targeting gastric and esophageal cancer markets.In non-cryotherapy products: Commercialized items such as the Pulmonary Nodule Localization Needle and Endoscopic Clip for Anastomosis, alongside pipeline products like the Atrial Fibrillation Pulsed Field Ablation (PFA) System and Anti-Gastroesophageal Reflux System, create complementary synergies.This "one-platform, multi-therapy" model endows Cryofocus with exceptional adaptability for indication expansion and pipeline sustainability. The Company currently boasts a robust portfolio of 23 products and candidates: 14 cryotherapy and 9 non-cryotherapy items, with 11 already commercialized. Such platform-based diversification is rare among single-therapy medical device firms, highlighting substantial long-term growth potential and risk resilience.Strong Financial Performance and Sustained Growth MomentumBeyond the revenue surge driven by respiratory products, Cryofocus’s interim results signal positive ongoing growth. The Company’s technological advantages further translated into financial resilience. Gross profit reached RMB34.3 million for the first half of 2025, up 124.5% year-on-year, with a solid gross profit margin of 67.1%. Enhanced R&D efficiency led to significantly reduced losses. R&D expenses optimized to RMB17.9 million (down 51.9% year-on-year), while the period loss narrowed 51.4% to RMB27.2 million, demonstrating a clear trend toward profitability. Cash reserves increased 40.1% from year-end 2024 to RMB63.7 million, providing a solid foundation for sustained R&D and market expansion.Revenue diversification and quality improved as high-value self-developed products (e.g., Malignant Stenosis Cryoablation System) launched and scaled, complemented by deepening collaboration with BSC. The significant reduction in R&D expenses reflects improved efficiency and reduced consumable needs as products advance, driven by optimized personnel costs and management enhancements. This establishes a sound framework for balancing innovation intensity with cost control.Furthermore, the Company increased investment in sales network development, with selling and distribution expenses rising 174.4% year-on-year to RMB9.2 million, underscoring proactive resource allocation to build marketing teams and promote newly launched products (e.g., Malignant Stenosis Cryoablation System), laying groundwork for future sales scale expansion.Global Peer Benchmark Highlights Valuation PotentialCryofocus’s technological strength in respiratory interventional cryotherapy, particularly in FDA-designated areas like asthma treatment, positions it competitively against global leaders.Benchmarked against Inspire Medical Systems (INSP) (focusing on OSA neurostimulation, differing in indication but similar in respiratory neuro-intervention): Inspire currently holds a market capitalization of US$2.279 billion and a trailing-twelve-month (TTM) P/E ratio of 44.28x. Cryofocus’s Asthma Cryoablation System similarly targets pulmonary vagal nerves via minimally invasive ablation, with an innovative pathway validated by FDA Breakthrough status. Yet, as a diversified platform innovator with a broad pipeline and multiple commercialized products, Cryofocus’s current Hong Kong market valuation (Inspire’s market cap is 12.8x Cryofocus’s) significantly trails Inspire’s.This substantial valuation gap, while influenced by factors such as differing markets (US vs. HK), stages of development (Inspire being profitable and established in the US market), and a single-product focus versus a platform model, nonetheless clearly underscores the significant upside potential in Cryofocus Medtech's current market valuation relative to its technological capabilities, the breadth of its product pipeline, and its potential for globalization breakthroughs. With the advancement of clinical progress for its respiratory intervention products (particularly the Asthma Cryoablation System COPD Cryospray System Peri-Pulmonary Nodule Cryoablation System), the clarification of overseas registration pathways, and the continued high-speed growth in its revenue scale, a market re-rating of its value represents a high-probability event. The current valuation level presents an attractive window of opportunity for investors bullish on the long-term prospects of the minimally-invasive interventional cryotherapy sector and the value inherent in a platform company model.Looking ahead, Cryofocus maintains a clear strategy: rapidly advance clinical development and commercialization of pipeline products; deepen focus on minimally invasive interventional cryotherapy while expanding the portfolio leveraging its core platforms; continuously invest in underlying and supporting technologies; and selectively expand global operations. The Company is steadily transitioning from R&D-driven to a dual-engine model integrating R&D and commercialization, advancing resolutely toward its vision of becoming a "global platform for minimally invasive interventional cryotherapy medical devices." Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - OMS Energy Technologies Inc. ("OMS Energy" or the "Company", stock code: OMSE) and Ministry XR ("Ministry XR"), a leading national institution for AI code governance and technical supervision in Singapore, officially signed a memorandum of understanding on 6 August 2025 to establish an in-depth strategic partnership between two parties. Leveraging AI-driven robotic coding technology and the cutting-edge engineering capabilities possessed by each other, OMS Energy and Ministry XR will jointly promote the intelligent transformation of the traditional energy industry, moving towards a more sustainable development future with high efficiency, low cost and high security.(Left) Mr. How Meng Hock, Chief Executive Officer of OMS Energy and Mr. Andrew Yew, Chief Technology Officer of Ministry XRThis cooperation focuses on the long-term strategic layout of "intelligently reshaping energy", aiming to build a complete ecosystem through three pillars:1.Frontier R&D in AI Robotic CodingOMS Energy and Ministry XR will jointly develop an exclusive AI-driven robotic coding framework tailored for the energy industry, with a focus on breaking through core scenarios such as predictive maintenance, autonomous operation, environmental compliance monitoring, and automation of safety protocols. This technology will significantly reduce human operation errors, eliminate personnel safety risks under different environmental conditions like extreme weather, steep terrain, a space filled with poisonous gas, remote area, etc, improve the uptime of energy infrastructure, and provide technical guarantees for the full-lifecycle inspection and maintenance of critical facilities such as oil and gas pipelines and wellhead systems.2.Commercialization and Large-Scale Market DeploymentTechnology implementation will quickly move from the laboratory to the industrial end: Ministry XR will assist OMS Energy in designing scalable commercialization pathways, including conducting pilot projects, integrating with existing industrial systems, and providing regulatory compliance and certification support. The two parties plan to develop export-grade technologies with global competitiveness, covering the core markets such as Asia-Pacific, the Middle East, and North Africa where OMS Energy currently operate to accelerate the popularization of intelligent solutions in the energy industry.3.Academic and Innovation Ecosystem CollaborationBuilding on OMS Energy's long-term R&D cooperation with institutions such as the A*Star Singapore Institute of Manufacturing Technology (SIMTech), OMS Energy and Ministry XR will jointly establish an "AI-Robotics Innovation Laboratory" with top academic institutions. They will develop professional courses, establish talent delivery channels, promote the direct transformation of scientific research achievements into industrial applications, and form a closed loop of "industry-research-application".Shared Vision: Let Intelligence and ESG Concepts become Industry StandardsMr. How Meng Hock, Chief Executive Officer of OMS Energy, added: "OMS Energy has been deeply engaged in the oil and gas engineering field for nearly 50 years, with 11 manufacturing bases in 6 countries and a professional team of over 600 people. Our core products, OCTG (Oil Country Tubular Goods) and SWS (Surface Wellhead Systems) have sold to over 200 high-quality customers worldwide. This cooperation with Ministry XR will accelerate our business expansion into a 'full-lifecycle pipeline inspection and maintenance service sector in oilfield and urban water supply and wastewater industry', making AI robotics technology the core engine for cost reduction, efficiency improvement, environmental risk elimination and green development in the energy industry. Safety operation is paramount in the oil and gas industry due to the inherent risks associated with the work. AI robotics technology will significantly reduce the risks involved in daily operations in oil and gas projects, especially in extreme climates and harsh geographical environments, and further ensure the sustainability, safety, and efficiency of operations."Mr. Andrew Yew, Chief Technology Officer of Ministry XR stated at the signing ceremony: "As a leading national institution for AI code governance and technical supervision in Singapore, we will participate in the full-lifecycle of OMS Energy projects, providing full-dimensional support from technology selection to strategic implementation. This cooperation is not only a response to the digital transformation of the energy industry but also a proactive layout to lead global energy technology standards."About OMS Energy Technologies Inc.OMS Energy Technologies Inc. is a seasoned engineering and technology enterprise in the upstream oil and gas development sector, specializing in the design, certification, and manufacturing of precision engineering systems. Its core products include OCTG (Oil Country Tubular Goods), SWS (Surface Wellhead Systems), and specialized connectors, while also providing value-added services such as advanced threading processing and pipeline inspection and maintenance. With business covering regions including Asia-Pacific, the Middle East, North Africa, and West Africa, and backed by authoritative certifications such as ISO 9001 and API Q1 as well as stable financial performance, the Company has become a trusted partner in the global energy industry.About Ministry XRMinistry XR is a leading national institution for AI code governance and technical supervision in Singapore, dedicated to promoting the standardized application and industrial implementation of AI and robotics technologies. It has profound industry know-how in fields such as technical standard formulation and evaluation of global cutting-edge technologies, providing strategic guidance and technical support for the digital transformation of key industries.This press release is issued by Messis Global on behalf of OMS Energy Technologies Inc.For investor and media inquiriesEmail: pr@messis-global.com Copyright 2025 ACN Newswire via SeaPRwire.com.